-
-
-
-
-
-
-
Taysha Gene Therapies (TSHA) PT Raised to $17 at Canaccord
-
-
-
-
-
-
-
Goldman Sachs Upgrades Taysha Gene Therapies (TSHA) to Buy
-
-
-
-
-
-
-
Taysha Gene Therapies regains full rights to TSHA-102 Rett syndrome program
-
-
-
-
-
-
-
BofA Securities Starts Taysha Gene Therapies (TSHA) at Buy
-
-
-
-
-
-
-
Taysha Gene Therapies (TSHA) Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
-
-
-
-
-
-
-
7 top biotech picks for 2025 according to Wells Fargo
-
-
-
-
-
-
-
Taysha Gene Therapies (TSHA) Tops Q2 EPS by 7c
-
429,217 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

